PE20231556A1 - Glucoformas de fab ricas en manosa - Google Patents

Glucoformas de fab ricas en manosa

Info

Publication number
PE20231556A1
PE20231556A1 PE2023001612A PE2023001612A PE20231556A1 PE 20231556 A1 PE20231556 A1 PE 20231556A1 PE 2023001612 A PE2023001612 A PE 2023001612A PE 2023001612 A PE2023001612 A PE 2023001612A PE 20231556 A1 PE20231556 A1 PE 20231556A1
Authority
PE
Peru
Prior art keywords
antibody
glucosylated
composition
mannose
beta
Prior art date
Application number
PE2023001612A
Other languages
English (en)
Inventor
Klaus Joeris
Neslihan Oezden
Wolfgang Richter
Britta Schmidt
Carsten Hofmann
Wilma Lau
Roland Staack
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20231556A1 publication Critical patent/PE20231556A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDO A UNA COMPOSICION QUE COMPRENDE UN ANTICUERPO MONOCLONAL GLUCOSILADO, EN LA QUE DICHO ANTICUERPO ES UN ANTICUERPO ANTI-BETA A HUMANO, UN ANTICUERPO BIESPECIFICO QUE COMPRENDE UN ANTICUERPO ANTI-BETA A HUMANO, O UN FRAGMENTO DE UN ANTICUERPO ANTI-BETA A HUMANO QUE COMPRENDE UNA REGION FAB GLUCOSILADA Y QUE PUEDE UNIRSE A BETA A, TENIENDO EL ANTICUERPO N-GLUCOSILACION EN LAS REGIONES FAB DEL MISMO, EN LA QUE EN RELACION CON LA CANTIDAD TOTAL DE FAB GLUCOSILADO EN LA COMPOSICION, 20 % O MENOS DE LAS REGIONES FAB EN LA COMPOSICION TIENEN UN GLUCANO RICO EN MANOSA UNIDO A N. TAMBIEN SE REFIERE A PROCEDIMIENTOS PARA LA REGULACION DURANTE EL CULTIVO DE UN MICROORGANISMO QUE EXPRESA UN ANTICUERPO MONOCLONAL CON CONTENIDO REGULADO DE GLUCOFORMAS DE FAB RICAS EN MANOSA. DICHA COMPOSICION ES UTIL EN EL DIAGNOSTICO O TRATAMIENTO DE DEMENCIA, ENFERMEDAD DE ALZHEIMER, NEUROPATIA MOTORA.
PE2023001612A 2020-11-16 2021-11-04 Glucoformas de fab ricas en manosa PE20231556A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207804 2020-11-16
PCT/EP2021/080692 WO2022101088A1 (en) 2020-11-16 2021-11-04 Fab high mannose glycoforms

Publications (1)

Publication Number Publication Date
PE20231556A1 true PE20231556A1 (es) 2023-10-03

Family

ID=73452078

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001612A PE20231556A1 (es) 2020-11-16 2021-11-04 Glucoformas de fab ricas en manosa

Country Status (13)

Country Link
US (1) US20240002483A1 (es)
EP (1) EP4244248A1 (es)
JP (1) JP2023549809A (es)
KR (1) KR20230109674A (es)
CN (1) CN116615231A (es)
AU (1) AU2021376837A1 (es)
CA (1) CA3200954A1 (es)
CL (1) CL2023001371A1 (es)
CR (1) CR20230253A (es)
IL (1) IL302740A (es)
MX (1) MX2023005581A (es)
PE (1) PE20231556A1 (es)
WO (1) WO2022101088A1 (es)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
PE20100748A1 (es) 2005-12-12 2010-11-12 Hoffmann La Roche Anticuerpo anti beta-4-amiloide que contiene asparagina glicosilada en la region variable de vh
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
KR102597804B1 (ko) 2013-12-20 2023-11-07 제넨테크, 인크. 이중 특이적 항체
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO

Also Published As

Publication number Publication date
JP2023549809A (ja) 2023-11-29
AU2021376837A1 (en) 2023-06-15
US20240002483A1 (en) 2024-01-04
IL302740A (en) 2023-07-01
EP4244248A1 (en) 2023-09-20
CN116615231A (zh) 2023-08-18
CL2023001371A1 (es) 2023-12-01
MX2023005581A (es) 2023-05-29
CA3200954A1 (en) 2022-05-19
WO2022101088A1 (en) 2022-05-19
KR20230109674A (ko) 2023-07-20
CR20230253A (es) 2023-07-26

Similar Documents

Publication Publication Date Title
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CY1115906T1 (el) Ανθρωποποιημενα αντισωματα κατα του βητα αμυλοειδους
JP2019518742A5 (es)
MA32725B1 (fr) Anticorps contre l'il 17 humaine et utilisations associees
MX2019013132A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
CY1115456T1 (el) Μεθοδος χορηγησης αντισωματων αντι-ιl-5
EA201790342A1 (ru) Антитела к trem2 и способы их применения
BR112016028043A2 (pt) composições farmacêuticas, e transportador farmaceuticamente aceitável e anticorpo monoclonal para igg3 humana ou humanizada
MX2017006323A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
BRPI0211953B8 (pt) anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
PE20080008A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
UY30003A1 (es) Anticuerpos glicosilados en la region variable
BRPI0210405B8 (pt) anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão
BRPI0408167A (pt) conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
JP2010502708A5 (es)
DK1713830T3 (da) Anti-epcam-immunglobuliner
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
BR112022001733A2 (pt) Anticorpos anti-ms4a4a e métodos de uso dos mesmos
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
PE20231556A1 (es) Glucoformas de fab ricas en manosa
MX2021000889A (es) Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
CL2022001984A1 (es) Composiciones métodos para aumentar, mejorar transducción vectores de terapia génica y para eliminar, reducir inmunoglobulinas